Premium
Development of a methotrexate educational guide/information/monitoring booklet for inflammatory arthritis
Author(s) -
Martin Una,
O'Gradaig Donncha,
Nolan Darragh Foley,
Sheehy Claire
Publication year - 2019
Publication title -
musculoskeletal care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.628
H-Index - 28
eISSN - 1557-0681
pISSN - 1478-2189
DOI - 10.1002/msc.1398
Subject(s) - medicine , patient education , methotrexate , alternative medicine , family medicine , health care , medical education , pathology , economics , economic growth
There are over 40,000 people living in Ireland with inflammatory arthritis (IA), a condition that is potentially destructive in nature and can have personal, social and economic consequences. Although we have witnessed dramatic changes in the treatment of IA in the last two decades, methotrexate (MTX) remains the first‐line treatment for patients with a diagnosis of IA. Despite the fact that MTX is so commonly prescribed, there is a lack of educational materials both for healthcare professionals (HCPs) and patients. The aim of the present study was to develop a suite of MTX material for patients. Methods A comprehensive literature review of MTX (evidence, educational materials and practice guidelines) in the treatment of IA was undertaken. The content of the documents was developed, and the format and structure of the documents were agreed. A tailored patient educational guide, information/monitoring booklet and alert card were designed to address the lack of educational materials for this condition. A national pilot study of the documents was conducted (a postal questionnaire for patients and electronic survey for clinical nurse specialists). Results and recommendations were incorporated into the final documents. These documents were also incorporated into the National Clinical Care Programme–rheumatology–methotrexate pathway. Results A 26‐page evidence‐based educational guide was produced to support the HCP in educating patients taking MTX, in conjunction with a patient information/monitoring booklet and alert card to support the patient. Conclusions These documents are now widely available and used in clinical practice in Ireland, providing patients with standardized, evidence‐based information about MTX.